Announcement

Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN (07-19-2018)
Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About... Continue Reading

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer (07-17-2018)
On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population... Continue Reading

Cyramza Improves Survival in Poor-Prognosis Liver Cancer (07-12-2018)
Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab)... Continue Reading

Anne Arundel Medical Center

Please click here to visit the DeCesaris Cancer Institute website

The DeCesaris Cancer Institute and AAMC Oncology and Hematology are now QOPI (Quality Oncology Practice Initiative) Certified. This demonstrates a commitment to excellence and ongoing quality improvement.
The goals of the QOPI Certification Program are:

1. Promote the highest quality cancer care as defined by the clinician experts.
2. Provide a trusted solution to satisfy external demand for quality activities.
3. Reduce redundant programs or requirements for oncology practices, including health plan programs.